Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 3/20 | 0.35 |
| ▸ | AGXT | P21549 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25231432 | 0.81 | HTR2A (0.42) | SMN1; SMN2 | |
| SCHEMBL30539480 | 0.81 | HTR2A (0.42) | SMN1; SMN2 | |
| SCHEMBL11131916 | 0.78 | MEN1 (0.40) | MEN1MAPTKMT2AALDH1A1HSP90AB1 | |
| SCHEMBL2776883 | 0.76 | MEN1 (0.41) | MEN1MAPTKMT2AALDH1A1HSP90AB1 | |
| SCHEMBL28568279 | 0.75 | ALDH1A1 (0.47) | MEN1MAPTKMT2AALDH1A1CYP3A4 | |
| SCHEMBL6159094 | 0.71 | MEN1 (0.43) | MEN1MAPTKMT2AALDH1A1HSP90AB1 | |
| SCHEMBL28725370 | 0.70 | DHFR (0.46) | MEN1MAPTKMT2AALDH1A1HSP90AB1 | |
| SCHEMBL10907646 | 0.69 | CD44 (0.41) | KMT2AALDH1A1HSP90AB1CYP3A4TAAR1 | |
| SCHEMBL15015630 | 0.69 | MAPT (0.42) | MEN1MAPTKMT2AALDH1A1HSP90AB1 | |
| SCHEMBL4192602 | 0.68 | DHFR (0.47) | ALDH1A1HSP90AB1ADCY10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189041-B1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2021-04-28 | — | — | EP | disclosed |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | MEN1 324/4885MAPT 3366/4885KMT2A 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.